Health ❯Healthcare ❯Pharmacology

Monoclonal Antibodies

Mechanism of Action Benralizumab Cetuximab Zigakibart Nirsevimab

Zigakibart sustains proteinuria remission and stabilizes kidney function over 100-week IgA nephropathy trial

Phase 1/2 results position APRIL pathway blockade as a key driver of pathogenic IgA1 reduction with a global Phase 3 trial underway.

Single Dose of Nirsevimab Halves Bronchiolitis Admissions in Infants Under Six Months

Avelumab and Cetuximab Combo Quadruples Progression-Free Survival in Advanced cSCC

New Injection Shows Promise as First Major Asthma and COPD Treatment Breakthrough in 50 Years

First New Asthma and COPD Treatment in 50 Years Shows Promise